To view this email as a web page, click here

Today's Rundown

Featured Story

Moderna scores COVID-19 vaccine backing in Europe, setting off another major vaccination push

Two weeks after European regulators endorsed Pfizer and BioNTech’s COVID-19 vaccine, a second shot is getting ready for a broad rollout in the region. Moderna scored regulatory support for its vaccine, enabling health officials to expand their vaccination push amid fresh lockdowns and increases in cases. 

read more

Top Stories

Study: Hospitals at or near full COVID-19 ICU capacity increase by 90% over past few months

A new study found a 90% increase in hospitals reaching near or full ICU bed capacity over the past few months as hospitals grapple with new surges of COVID-19.

read more

UC San Diego deploys COVID-19 test vending machines for returning students

As universities nationwide begin a new semester under the COVID-19 pandemic, the University of California, San Diego is making diagnostic screening a more ubiquitous fixture of day-to-day life by offering tests in sidewalk vending machines.

read more

Biopharma roundup—States to pull shots from sluggish hospitals

AstraZeneca's shot is now authorized in six countries. Serum Institute won't be able to export AZ's shot for several months, CEO Adar Poonawalla said. New York and Florida told hospitals deploying COVID vaccines to pick up the pace. Meanwhile, NIAID director Anthony Fauci thinks the U.S. could soon hit 1 million vaccinations per day.

read more

Healthcare roundup—CVS expects to complete first nursing home inoculations this month

Follow along with the latest COVID-19 news straight from the Fierce Healthcare team.

read more

Regeneron’s CEO and CSO could nab a whopping $1.4B in bonuses—if the pipeline pumps up investors

Regeneron CEO Leonard Schleifer and CSO George Yancopoulos just won rejigged performance-pay plans that promise a combined payday of up to $1.4 billion eight years from now. But their ability to nab those bonuses will rely on Regeneron's ability to grow market share for hits like Dupixent, while also getting novel drugs out of the pipeline.

read more